1
|
Shen Z, Gao X, Huang D, Xu X, Shen J. The potential of Gynostemma pentaphyllum in the treatment of hyperlipidemia and its interaction with the LOX1-PI3K-AKT-eNOS pathway. Food Sci Nutr 2024; 12:8000-8012. [PMID: 39479713 PMCID: PMC11521742 DOI: 10.1002/fsn3.4250] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/29/2024] [Revised: 05/09/2024] [Accepted: 05/15/2024] [Indexed: 11/02/2024] Open
Abstract
Gynostemma pentaphyllum, a traditional Chinese medicine, is widely used to treat various diseases, but its therapeutic effects and mechanisms of action on hyperlipidemia remain unclear. This study aims to investigate the effects of Danshen leaf on hyperlipidemia through network pharmacology, molecular docking, and cellular experiments, elucidating its multifaceted mechanism of action within the LOX1-PI3K-AKT-eNOS pathway. First, the active ingredients and targets of G. pentaphyllum were screened using the Traditional Chinese Medicine Systems Pharmacology database. Then, targets for hyperlipidemia were identified using the OMIM and GeneCards databases, and potential therapeutic targets for G. pentaphyllum in treating hyperlipidemia were determined. An active ingredient-target network was constructed using Cytoscape software, and a protein-protein interaction (PPI) network was built and visualized using the STRING database and Cytoscape software. Finally, GO functional and KEGG pathway enrichment analyses were performed, and the predicted mechanisms were validated through molecular docking and cell experiments. 85 targets for G. pentaphyllum and 1556 for Hyperlipidemia were screened, with 53 common targets. Twenty-four active ingredients of G. pentaphyllum were found to be involved in the treatment of hyperlipidemia. Key nodes such as Rhamnazin, Isofucosterol, and quercetin, and targets NCOA2, NR3C2, PGR, and PPARG showed high relevance. In the PPI network, 8 nodes, including IL6, PPARG, and VEGFA, exhibited high centrality. GO functional and KEGG pathway enrichment analyses indicated that G. pentaphyllum may treat hyperlipidemia by influencing various biological functions and pathways, such as DNA-binding transcription factor binding, RNA polymerase II-specific DNA-binding transcription factor binding, and lipid and atherosclerosis. Cell experiments demonstrated that G. pentaphyllum significantly regulated the expression of key proteins in the LOX1-PI3K-AKT-eNOS pathway, thereby improving hyperlipidemia. G. pentaphyllum improves hyperlipidemia by mediating the LOX1-PI3K-AKT-eNOS pathway. This study provides a new theoretical basis and experimental evidence for applying G. pentaphyllum to treating hyperlipidemia.
Collapse
Affiliation(s)
- Zhuyang Shen
- Affiliated Hospital of Integrated Traditional Chinese and Western MedicineNanjing University of ChineseNanjingChina
- Jiangsu Province Academy of Traditional Chinese MedicineNanjingChina
| | - Xin Gao
- Affiliated Hospital of Integrated Traditional Chinese and Western MedicineNanjing University of ChineseNanjingChina
- Jiangsu Province Academy of Traditional Chinese MedicineNanjingChina
| | - Dan Huang
- Affiliated Hospital of Integrated Traditional Chinese and Western MedicineNanjing University of ChineseNanjingChina
- Jiangsu Province Academy of Traditional Chinese MedicineNanjingChina
| | - Xiaojin Xu
- Affiliated Hospital of Integrated Traditional Chinese and Western MedicineNanjing University of ChineseNanjingChina
- Jiangsu Province Academy of Traditional Chinese MedicineNanjingChina
| | - Jianping Shen
- Affiliated Hospital of Integrated Traditional Chinese and Western MedicineNanjing University of ChineseNanjingChina
- Jiangsu Province Academy of Traditional Chinese MedicineNanjingChina
| |
Collapse
|
2
|
He S, Li H, Zhang Q, Zhao W, Li W, Dai C, Li B, Cheng J, Wu S, Zhou Z, Yang J, Li S. Berberine alleviates inflammation in polycystic ovary syndrome by inhibiting hyaluronan synthase 2 expression. PHYTOMEDICINE : INTERNATIONAL JOURNAL OF PHYTOTHERAPY AND PHYTOPHARMACOLOGY 2024; 128:155456. [PMID: 38537446 DOI: 10.1016/j.phymed.2024.155456] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/28/2023] [Revised: 02/03/2024] [Accepted: 02/14/2024] [Indexed: 05/01/2024]
Abstract
BACKGROUND Polycystic ovary syndrome (PCOS) is a heterogeneous metabolic and endocrine disorder that causes anovulatory infertility and abnormal folliculogenesis in women of reproductive age. Several studies have revealed inflammation in PCOS follicles, and recent evidence suggests that Berberine (BBR) effectively reduces inflammatory responses in PCOS, however, the underlying mechanisms remain unclear. PURPOSE To determine the underlying mechanisms by which BBR alleviates inflammation in PCOS. STUDY DESIGN Primary human GCs from healthy women and women with PCOS, and KGN cells were used for in vitro studies. ICR mice were used for in vivo studies. METHODS Gene expression was measured using RT-qPCR. HAS2, inflammatory cytokines, and serum hormones were assayed by ELISA. Protein expression profiles were assayed by Western blot. Chronic low-grade inflammatory mouse models were developed by intraperitoneal injection with LPS, and PCOS mouse models were established by subcutaneous intraperitoneal injection of DHEA. BBR and 4-MU were administered by gavage. Ovarian morphologic changes were evaluated using H&E staining. HAS2 expression in the ovary was assayed using Western blot and immunohistochemistry. RESULTS Our results confirmed that HAS2 expression and hyaluronan (HA) accumulation are closely associated with inflammatory responses in PCOS. Data obtained from in vitro studies showed that HAS2 and inflammatory genes (e.g., MCP-1, IL-1β, and IL-6) are significantly upregulated in PCOS samples and LPS-induced KGN cells compared to their control groups. In addition, these effects were reversed by blocking HAS2 expression or HA synthesis using BBR or 4-MU, respectively. Furthermore, HAS2 overexpression induces the expression of inflammatory genes in PCOS. These results were further confirmed in LPS- and DHEA-induced mouse models, where inflammatory genes were reduced by BBR or 4-MU, and ovarian morphology was restored. CONCLUSIONS Our results define previously unknown links between HAS2 and chronic low-grade inflammation in the follicles of women with PCOS. BBR exerts its anti-inflammatory effects by down-regulating HAS2. This study provides a novel therapeutic target for alleviating ovarian inflammation in women with PCOS.
Collapse
Affiliation(s)
- Shaojing He
- Reproductive Medical Center, Renmin Hospital of Wuhan University, Jiefang Road 238, Wuhan, 430060, China; Jiangsu Key Laboratory for Food Quality and Safety-State Key Laboratory Cultivation Base of Ministry of Science and Technology, Institute of Animal Science, Jiangsu Academy of Agricultural Sciences, Nanjing, 210014, China
| | - Hui Li
- Jiangsu Key Laboratory for Food Quality and Safety-State Key Laboratory Cultivation Base of Ministry of Science and Technology, Institute of Animal Science, Jiangsu Academy of Agricultural Sciences, Nanjing, 210014, China; Jiangsu Provincial Engineering Research Center for Precision Animal Breeding, Nanjing, 210014, China
| | - Qianjie Zhang
- Reproductive Medical Center, Renmin Hospital of Wuhan University, Jiefang Road 238, Wuhan, 430060, China; Jiangsu Key Laboratory for Food Quality and Safety-State Key Laboratory Cultivation Base of Ministry of Science and Technology, Institute of Animal Science, Jiangsu Academy of Agricultural Sciences, Nanjing, 210014, China
| | - Weimin Zhao
- Jiangsu Key Laboratory for Food Quality and Safety-State Key Laboratory Cultivation Base of Ministry of Science and Technology, Institute of Animal Science, Jiangsu Academy of Agricultural Sciences, Nanjing, 210014, China; Jiangsu Provincial Engineering Research Center for Precision Animal Breeding, Nanjing, 210014, China
| | - Wei Li
- Reproductive Medical Center, Renmin Hospital of Wuhan University, Jiefang Road 238, Wuhan, 430060, China
| | - Chaohui Dai
- Jiangsu Key Laboratory for Food Quality and Safety-State Key Laboratory Cultivation Base of Ministry of Science and Technology, Institute of Animal Science, Jiangsu Academy of Agricultural Sciences, Nanjing, 210014, China; Jiangsu Provincial Engineering Research Center for Precision Animal Breeding, Nanjing, 210014, China
| | - Bixia Li
- Jiangsu Key Laboratory for Food Quality and Safety-State Key Laboratory Cultivation Base of Ministry of Science and Technology, Institute of Animal Science, Jiangsu Academy of Agricultural Sciences, Nanjing, 210014, China; Jiangsu Provincial Engineering Research Center for Precision Animal Breeding, Nanjing, 210014, China
| | - Jinhua Cheng
- Jiangsu Key Laboratory for Food Quality and Safety-State Key Laboratory Cultivation Base of Ministry of Science and Technology, Institute of Animal Science, Jiangsu Academy of Agricultural Sciences, Nanjing, 210014, China; Jiangsu Provincial Engineering Research Center for Precision Animal Breeding, Nanjing, 210014, China
| | - Shuang Wu
- Hubei Provincial Hospital of Traditional Chinese Medicine Affiliated to Hubei University of Traditional Chinese Medicine, Wuhan, 430060, China
| | - Zhongming Zhou
- Hubei Provincial Hospital of Traditional Chinese Medicine Affiliated to Hubei University of Traditional Chinese Medicine, Wuhan, 430060, China
| | - Jing Yang
- Reproductive Medical Center, Renmin Hospital of Wuhan University, Jiefang Road 238, Wuhan, 430060, China
| | - Saijiao Li
- Reproductive Medical Center, Renmin Hospital of Wuhan University, Jiefang Road 238, Wuhan, 430060, China.
| |
Collapse
|
3
|
Wang M, Yang L, Sun G, Shao Y, Liu Y, Yang H, Wang Y, Zhang M, Shang Y, Gu X. Assessment of the Effect of Leonurine Hydrochloride in a Mouse Model of PCOS by Gene Expression Profiling. Genes (Basel) 2024; 15:507. [PMID: 38674441 PMCID: PMC11050333 DOI: 10.3390/genes15040507] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2024] [Revised: 04/13/2024] [Accepted: 04/16/2024] [Indexed: 04/28/2024] Open
Abstract
Polycystic ovary syndrome (PCOS) is an endocrine disease commonly associated with metabolic disorders in females. Leonurine hydrochloride (Leo) plays an important role in regulating immunity, tumours, uterine smooth muscle, and ovarian function. However, the effect of Leo on PCOS has not been reported. Here, we used dehydroepiandrosterone to establish a mouse model of PCOS, and some mice were then treated with Leo by gavage. We found that Leo could improve the irregular oestros cycle of PCOS mice, reverse the significantly greater serum testosterone (T) and luteinising hormone (LH) levels, significantly reduce the follicle-stimulating hormone (FSH) level, and significantly increase the LH/FSH ratio of PCOS mice. Leo could also change the phenomenon of ovaries in PCOS mice presented with cystic follicular multiplication and a lacking corpus luteum. Transcriptome analysis identified 177 differentially expressed genes related to follicular development between the model and Leo groups. Notably, the cAMP signalling pathway, neuroactive ligand-receptor interactions, the calcium signalling pathway, the ovarian steroidogenesis pathway, and the Lhcgr, Star, Cyp11a, Hsd17b7, Camk2b, Calml4, and Phkg1 genes may be most related to improvements in hormone levels and the numbers of ovarian cystic follicles and corpora lutea in PCOS mice treated by Leo, which provides a reference for further study of the mechanism of Leo.
Collapse
Affiliation(s)
- Mengmeng Wang
- College of Animal Science and Technology, Shihezi University, Shihezi 832000, China; (M.W.); (G.S.); (Y.S.); (Y.L.); (H.Y.); (Y.W.); (M.Z.); (Y.S.)
| | - Li Yang
- College of Veterinary Medicine, Xinjiang Agricultural University, Urumqi 830052, China;
| | - Guojie Sun
- College of Animal Science and Technology, Shihezi University, Shihezi 832000, China; (M.W.); (G.S.); (Y.S.); (Y.L.); (H.Y.); (Y.W.); (M.Z.); (Y.S.)
| | - Yongbin Shao
- College of Animal Science and Technology, Shihezi University, Shihezi 832000, China; (M.W.); (G.S.); (Y.S.); (Y.L.); (H.Y.); (Y.W.); (M.Z.); (Y.S.)
| | - Yuran Liu
- College of Animal Science and Technology, Shihezi University, Shihezi 832000, China; (M.W.); (G.S.); (Y.S.); (Y.L.); (H.Y.); (Y.W.); (M.Z.); (Y.S.)
| | - Huiying Yang
- College of Animal Science and Technology, Shihezi University, Shihezi 832000, China; (M.W.); (G.S.); (Y.S.); (Y.L.); (H.Y.); (Y.W.); (M.Z.); (Y.S.)
| | - Yan Wang
- College of Animal Science and Technology, Shihezi University, Shihezi 832000, China; (M.W.); (G.S.); (Y.S.); (Y.L.); (H.Y.); (Y.W.); (M.Z.); (Y.S.)
| | - Mengyuan Zhang
- College of Animal Science and Technology, Shihezi University, Shihezi 832000, China; (M.W.); (G.S.); (Y.S.); (Y.L.); (H.Y.); (Y.W.); (M.Z.); (Y.S.)
| | - Yunxia Shang
- College of Animal Science and Technology, Shihezi University, Shihezi 832000, China; (M.W.); (G.S.); (Y.S.); (Y.L.); (H.Y.); (Y.W.); (M.Z.); (Y.S.)
| | - Xinli Gu
- College of Animal Science and Technology, Shihezi University, Shihezi 832000, China; (M.W.); (G.S.); (Y.S.); (Y.L.); (H.Y.); (Y.W.); (M.Z.); (Y.S.)
| |
Collapse
|
4
|
Gong C, Pan L, Jiang Y, Sun Y, Han Y, Wang D, Wang Y. Investigating the mechanism of action of Yanghe Pingchuan Granule in the treatment of bronchial asthma based on bioinformatics and experimental validation. Heliyon 2023; 9:e21936. [PMID: 38027735 PMCID: PMC10654227 DOI: 10.1016/j.heliyon.2023.e21936] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2023] [Revised: 10/30/2023] [Accepted: 10/31/2023] [Indexed: 12/01/2023] Open
Abstract
Background Yanghe Pingchuan Granule (YPG) is a patented Chinese medicine developed independently by the Anhui Provincial Hospital of Traditional Chinese Medicine. For many years, it has been used for the treatment of asthma with remarkable clinical effects. However, the composition of YPG is complex, and its potential active ingredients and mechanism of action for the treatment of asthma are unknown. Materials and methods In this study, we investigated the potential mechanism of action of YPG in the treatment of asthma through a combination of bioinformatics and in vivo experimental validation. We searched for active compounds in YPG and asthma targets from multiple databases and obtained common targets. Subsequently, a protein-protein interaction (PPI) network for compound disease was constructed using the protein interaction database for Gene Ontology (GO) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis. Finally, hematoxylin and eosin (H&E) staining, Masson staining, enzyme-linked immunosorbent assay (ELISA) analysis, immunofluorescence (IF) experiments, and Western blot (WB) experiments were performed to verify the possible mechanism of action of YPG for asthma treatment. Results We obtained 72 active ingredients and 318 drug target genes that overlap with asthma. Serine/threonine-protein kinase (AKT1), tumor protein p53 (TP53), tumor necrosis factor (TNF), interleukin (IL)-6, IL-1β, vascular endothelial growth factor-A (VEGFA), prostaglandin-endoperoxide synthase 2 (PTGS2), caspase-3 (CASP3), mitogen-activated protein kinase 3 (MAPK3) and epidermal growth factor receptor (EGFR) were the most relevant genes in the PPI network. KEGG analysis showed a high number of genes enriched for the nuclear factor kappa-B (NF-κB) signaling pathway. Animal experiments confirmed that YPG reduced inflammatory cell infiltration and down-regulated the expression of ovalbumin-induced inflammatory factors. Furthermore, YPG treatment decreased the protein expression of NFĸB1, nuclear factor kappa B kinase subunit beta (IKBKB), vascular endothelial growth factor (VEGF), and vascular endothelial growth factor receptor 2 (VEGFR2) in lung tissue. Conclusion YPG has a positive effect on asthma by interfering with multiple targets. Furthermore, YPG may significantly inhibit the follicle-induced inflammatory response through the NF-ĸB signaling pathway.
Collapse
Affiliation(s)
- Chunxia Gong
- The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, Anhui, 230031, China
- College of Pharmacy, Anhui University of Chinese Medicine, Hefei, Anhui, 230038, China
| | - Lingyu Pan
- The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, Anhui, 230031, China
| | - Yeke Jiang
- The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, Anhui, 230031, China
- College of Pharmacy, Anhui University of Chinese Medicine, Hefei, Anhui, 230038, China
| | - Yehong Sun
- The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, Anhui, 230031, China
- College of Pharmacy, Anhui University of Chinese Medicine, Hefei, Anhui, 230038, China
| | - Yanquan Han
- The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, Anhui, 230031, China
| | - Dianlei Wang
- College of Pharmacy, Anhui University of Chinese Medicine, Hefei, Anhui, 230038, China
| | - Yongzhong Wang
- The First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, Anhui, 230031, China
| |
Collapse
|
5
|
Expression of genes in the AKT signalling pathway in human oocytes from patients with polycystic ovaries. ZYGOTE 2023; 31:237-239. [PMID: 36919849 DOI: 10.1017/s096719942200048x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/16/2023]
Abstract
Polycystic ovary syndrome is an endocrine disorder commonly found among females of reproductive age. Different factors have been correlated with this syndrome, although the aetiology of the disease is still unrecognized with both environmental and hereditary factors leading to the progression. Hormonal effects of the AKT pathway have made it an interesting study unit for PCOS cases. The aim of this study was to investigate the expression patterns of genes involved in the AKT pathway, including IRS1, IRS2, AKT1 and AKT2. In total, 13 human oocytes were collected for this study at the meiosis II stage, in which seven of them were collected from individuals with polycystic ovaries and the rest formed the control group of individuals with no signs of polycystic ovaries. RNA was extracted from oocytes and then the RNA was converted into cDNA for the real-time PCR process. Expression levels of four genes in the AKT pathway, in addition to housekeeping gene (ACTB), were evaluated. Expression levels of each gene were quantified using real-time PCR and statistical analysis was performed. The results of this study showed that there was no significant correlation between the expression of genes in oocyte samples obtained from patients with polycystic ovaries and the control group. This study is the first to evaluate the expression levels of genes involved in the AKT pathway in human oocyte samples. Therefore, it provides crucial information to form the basis of further studies.
Collapse
|
6
|
Wang Z, Cui Q, Shi L, Zhang M, Song P, Duan D, Guo W. Network Pharmacology-Based Prediction and Verification of Shikonin for the mechanism treating colorectal cancer. Recent Pat Anticancer Drug Discov 2021; 17:297-311. [PMID: 34951580 DOI: 10.2174/1574892817666211224142100] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2021] [Revised: 11/19/2021] [Accepted: 11/27/2021] [Indexed: 11/22/2022]
Abstract
BACKGROUND Shikonin (SKN), a naturally occurring naphthoquinone, is a major active chemical component isolated from Lithospermum erythrorhizon Sieb Zucc, Arnebia euchroma (Royle) Johnst, or Arnebia guttata Bunge, and commonly used to treat viral infection, inflammation, and cancer. However, the underlying mechanism has not been elucidated. OBJECTIVE This study aims to explore the antitumor mechanism of SKN in colorectal cancer (CRC) through network pharmacology and cell experiments. METHODS Using SymMap database and Genecards to predict the potential targets of SKN and CRC, while the cotargets were obtained by Venn diagram. The cotargets were imported into website of String and DA DAVID, constructing the protein-protein interaction (PPI) network, performing Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses, the Compound-Target-Pathway (C-T-P) network was generated by connecting potential pathways with the corresponding targets. RESULTS According to the results of network pharmacological analysis, the cell experiments were used to verify the key signal pathway. The most relevant target of SKN for the treatment of CRC was PI3K/Akt signaling pathway. SKN inhibited CRC cells (HT29 and HCT116) proliferation, migration, and invasion, and promoted cell apoptosis by targeting IL6 and inhibiting the IL6R/PI3K/Akt signaling pathway. SKN promotes apoptosis and suppresses CRC cells (HT29 and HCT116) activity through the PI3K-Akt signaling pathway. CONCLUSION This research not only provides a theoretical and experimental basis for more in-depth studies but also offers an efficient method for the rational utilization of a series of Traditional Chinese medicines as anti-CRC drugs.
Collapse
Affiliation(s)
- Zefeng Wang
- The Research Center of Chiral Drugs, Innovation Research Institute of Traditional Chinese Medicine (IRI), Shanghai University of Traditional Chinese Medicine, China
| | - Qianfei Cui
- The Research Center of Chiral Drugs, Innovation Research Institute of Traditional Chinese Medicine (IRI), Shanghai University of Traditional Chinese Medicine, China
| | - Ling Shi
- Honghe University, Mengzi 661199, China
| | - Meiling Zhang
- Research Center of Traditional Chinese Medicine, Gansu Province, Gansu University of Chinese Medicine, Lanzhou 730000, China
| | - Peng Song
- The Research Center of Chiral Drugs, Innovation Research Institute of Traditional Chinese Medicine (IRI), Shanghai University of Traditional Chinese Medicine, China
| | - Dongzhu Duan
- Shanxi Key Laboratory of Phytochemistry and College of Chemistry & Chemical Engineering, Baoji University of Arts and Sciences, Baoji, 721013, China
| | - Wenjing Guo
- Research Center of Traditional Chinese Medicine, Gansu Province, Gansu University of Chinese Medicine, Lanzhou 730000, China
| |
Collapse
|